GURU.Markets stock price, segment price, and overall market index valuation
The company's share price PainReform Ltd.
PainReform is a pharmaceutical company developing long-acting pain medications. Its stock price is a bet that its product will become a successful alternative to existing post-operative pain relief methods.
Share prices of companies in the market segment - Pharma other
PainReform is an Israeli pharmaceutical company developing long-acting medications for postoperative pain relief to reduce the need for opioids. We classified it in the "Other Pharmaceuticals" category. The chart below shows how the market is evaluating new approaches to pain treatment.
Broad Market Index - GURU.Markets
PainReform is an Israeli pharmaceutical company developing extended-release medications for post-operative pain relief. It is a component of the GURU.Markets index. The chart below shows the US market. See how this company's stock compares to the US market.
Change in the price of a company, segment, and market as a whole per day
PRFX - Daily change in the company's share price PainReform Ltd.
PainReform Ltd.'s daily share price fluctuations reflect the high volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its post-operative pain management drugs.
Daily change in the price of a set of shares in a market segment - Pharma other
PainReform develops non-opioid, extended-release analgesics for post-operative pain relief. The pharmaceutical sector working on opioid alternatives is volatile. The chart below reflects the average fluctuations in this niche, helping to assess the risks and potential of PRFX.
Daily change in the price of a broad market stock, index - GURU.Markets
PainReform is an Israeli pharmaceutical company developing long-acting painkillers. This innovative company's shares react to research data and regulatory decisions, contributing to overall volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization PainReform Ltd.
PainReform Ltd.'s year-over-year performance is a story about the development of its post-operative pain relief drug. Its 12-month market capitalization is entirely dependent on clinical trial data. The success of its extended-release formulation of ropivacaine could offer patients longer-lasting pain relief and reduce the need for opioids.
Annual dynamics of market capitalization of the market segment - Pharma other
PainReform, a late-stage biotech company developing painkillers, is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs in this vast but complex field of medicine.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
PainReform is a biotech company focused on one specific problem: post-surgical pain. Its performance relative to the market is purely a matter of anticipation of clinical trial results. Success of its drug could lead to explosive growth, while failure could lead to a near-total loss of value.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization PainReform Ltd.
PainReform is a biopharmaceutical company developing long-acting pain medications. Its monthly performance is entirely dependent on the results of its clinical trials. News about the progress of its lead drug is the main driver.
Monthly dynamics of market capitalization of the market segment - Pharma other
Developing new forms of pain medication is a critical task, especially in light of the opioid crisis. The dynamics of this pharmaceutical sector, shown in the graph, reflect the need for innovation. Companies like PainReform are pursuing research in this area.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
PainReform is a clinical-stage biotech company. Its shares are caught in a world of laboratory data and investor expectations about science. Their value can fluctuate wildly, ignoring any macroeconomic events or general market movements.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization PainReform Ltd.
Shares of PainReform, an Israeli company developing long-acting painkillers, are extremely volatile. Weekly price movements depend entirely on clinical trial results and regulatory decisions. The chart below visualizes how hopes and disappointments in this specific area of pharmaceuticals influence the stock price.
Weekly dynamics of market capitalization of the market segment - Pharma other
PainReform is developing a new long-acting pain reliever formula. This is a potentially large market, but the path to it requires expensive and time-consuming clinical trials. Compare the company's performance with the pharmaceutical sector to see how its narrow specialization and dependence on a single product impact its volatility.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
PainReform is a biopharmaceutical company. This chart shows how its weekly performance is independent of the broader market. Its stock price movements are driven solely by news about the progress of its drug candidates' clinical trials, not by the S&P 500.
Market capitalization of the company, segment and market as a whole
PRFX - Market capitalization of the company PainReform Ltd.
The valuation of PainReform Ltd. on the chart is a bet on its drug for long-term post-surgical pain relief. This Israeli biotech company's market cap depends on the success of its clinical trials and regulatory approval. The dynamics show how investors assess its potential in the vast pain relief market.
PRFX - Share of the company's market capitalization PainReform Ltd. within the market segment - Pharma other
PainReform's market share is focused on addressing one major problem: post-operative pain. Its market share is based on the potential of its sustained-release formulation, which could become a new standard in pain management and reduce the need for opioids.
Market capitalization of the market segment - Pharma other
This chart shows the total market capitalization of pharmaceutical companies developing new forms of pain medication. PainReform is a niche player in this field. The dynamics in the chart reflect the importance of finding effective and non-addictive analgesics.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart depicts the market value of post-surgical pain management. PainReform Ltd.'s market capitalization is the valuation of its innovative, long-acting pain reliever. The line shows how a small Israeli pharmaceutical company is attempting to address a global problem and gain market share.
Book value capitalization of the company, segment and market as a whole
PRFX - Book value capitalization of the company PainReform Ltd.
PainReform Ltd.'s book value represents its scientific capital. The chart below reflects the valuation of its intellectual property for PRF-110, a long-acting postoperative pain reliever. The pipeline's growth signals progress in clinical development, which is the company's primary asset.
PRFX - Share of the company's book capitalization PainReform Ltd. within the market segment - Pharma other
PainReform's tangible assets include its R&D infrastructure, which is focused on developing long-acting non-opioid pain relievers. The chart shows its share of this highly specialized scientific base, which forms the foundation for the creation of new solutions in postoperative pain management.
Market segment balance sheet capitalization - Pharma other
Biotechnology is a world of contrasts. The graph shows the massive manufacturing facilities of pharmaceutical giants. PainReform, as a development company, has a more streamlined model. Its value lies in its intellectual property rights to post-operative pain relief drugs, not in its scale of production.
Book value of all companies included in the broad market index - GURU.Markets
PainReform is developing a new long-acting pain reliever formula for the post-operative period. The company's assets are not massive factories, but patents and clinical trials aimed at solving a real medical problem. The chart below shows the material significance of this innovation in anesthesiology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - PainReform Ltd.
PainReform is an Israeli pharmaceutical company developing long-acting pain relief medications. Its market capitalization is based on the valuation of its leading product and its potential to change the standard of postoperative pain management.
Market to book capitalization ratio in a market segment - Pharma other
PainReform Ltd. is a pharmaceutical company developing drugs for post-operative pain relief. Its value depends on the success of its lead product in clinical trials. This chart shows how its market valuation, which reflects the commercial potential of its drug, relates to its tangible assets.
Market to book capitalization ratio for the market as a whole
PainReform is a pharmaceutical company developing non-opioid painkillers. The company's market valuation, shown in this chart, is based on the expected success of its lead drug in clinical trials. This is a classic example of biotech, where intellectual property is valued far more than tangible assets.
Debts of the company, segment and market as a whole
PRFX - Company debts PainReform Ltd.
PainReform, a clinical-stage pharmaceutical company, is using raised capital to develop its extended-release pain medication. This chart shows how the company is funding its clinical trials in an effort to offer a new alternative in the vast postoperative pain relief market.
Market segment debts - Pharma other
PainReform is an Israeli clinical-stage pharmaceutical company developing a new long-acting painkiller formulation. Its financial structure is typical for a biotech company. This chart shows how its debt policy reflects its capital requirements for clinical trials and regulatory approval for its lead product.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio PainReform Ltd.
Virax Biolabs operates in the medical diagnostics field, developing tests for viral diseases. R&D in this area requires significant investment. This chart shows how the company uses capital to fund its research and development, which is key to its ability to bring new diagnostic solutions to market.
Market segment debt to market segment book capitalization - Pharma other
PainReform is an Israeli clinical-stage pharmaceutical company developing a long-acting, non-opioid pain reliever for post-operative use. This chart compares its debt to the overall market capitalization of the pharmaceutical sector. It shows how the company is funding its research in its quest to offer an alternative to traditional painkillers.
Debt to book value of all companies in the market
PainReform Ltd. is an Israeli pharmaceutical company developing long-acting pain medications. The path from development to approval of a new drug is long and expensive. This graph of total market debt shows the financial environment in which the company is raising capital to conduct clinical trials aimed at addressing post-surgical pain.
P/E of the company, segment and market as a whole
P/E - PainReform Ltd.
For PainReform, a pharmaceutical company developing painkillers, the P/E ratio is irrelevant. The company has no stable profitability. Its valuation on this chart is arbitrary. Its true value is determined by the potential of its scientific developments and the results of its clinical trials.
P/E of the market segment - Pharma other
PainReform is an Israeli pharmaceutical company developing a long-acting pain reliever for postoperative use. Their goal is to reduce the need for opioids after surgery. This chart shows the average rating for the pharmaceutical sector, reflecting how the market values solutions aimed at combating the opioid crisis.
P/E of the market as a whole
PainReform Ltd. is an Israeli pharmaceutical company developing a long-acting pain reliever for post-operative use. The company's product is designed to reduce the need for opioids. This chart, reflecting overall sentiment, helps understand how investors view companies working to address the opioid crisis.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company PainReform Ltd.
PainReform is an Israeli pharmaceutical company developing a long-acting pain reliever for post-operative use. This chart reflects market expectations for the success of its key product. Future revenue depends on clinical trial results and potential regulatory approval.
%20P%2FE%20PainReform%20Ltd.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-PainReform-Ltd.&v=1772564115417 "Chart of the company's future (projected) P/E PainReform Ltd.")
Future (projected) P/E of the market segment - Pharma other
PainReform is a biopharmaceutical company developing a long-acting pain reliever for post-operative use. This chart shows how the market perceives the likelihood of its product's success. It compares investor expectations for PainReform with those of other companies seeking to offer an alternative to opioid analgesics.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-other&v=1772564115460 "Future (projected) P/E graph of the market segment - Pharma other")
Future (projected) P/E of the market as a whole
PainReform develops extended-release pain medications for post-operative use. Commercialization of their products depends on successful clinical trials and acceptance by the medical community. The overall market optimism shown by this chart is fueling capital flows into the biotech sector, which is essential for bringing new drugs to market.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772564115502 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit PainReform Ltd.
PainReform is a biopharmaceutical company developing long-acting non-opioid pain medications. Being in the clinical stage, its financial activities are focused on R&D. This chart illustrates the company's financial position, whose future value depends on the successful completion of clinical trials and the commercialization of its lead product.
Profit of companies in the market segment - Pharma other
PainReform Ltd. is a pharmaceutical company developing a non-opioid drug for extended-release post-surgical pain relief. This chart, showing overall sector profitability, reflects the search for alternatives to opioids. Successful commercialization of PainReform's product could not only capture significant market share but also impact treatment standards across the industry.
Overall market profit
PainReform is a pharmaceutical company developing a long-acting, non-opioid pain reliever. Its mission is to offer a safer alternative for post-operative pain relief. The company's success depends on clinical trial results and regulatory approval, not the state of the broader economy.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company PainReform Ltd.
PainReform is a biopharmaceutical company developing a non-opioid pain reliever for post-operative use. The revenue projections presented here are speculative and depend on the results of clinical trials and subsequent regulatory approval. The chart reflects expectations for the commercial potential of this product.
%20profit%20of%20the%20company%20PainReform%20Ltd.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-PainReform-Ltd.&v=1772564115602 "Graph of future (projected) profit of the company PainReform Ltd.")
Future (predicted) profit of companies in the market segment - Pharma other
PainReform develops non-opioid, extended-release pain medications for post-operative use. This chart shows revenue forecasts for the entire pharmaceutical sector. It helps understand how the company's product, aimed at addressing acute pain without the risk of addiction, compares to overall trends in healthcare and the pharmaceutical industry.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-other&v=1772564115661 "Graph of future (predicted) profits of companies in a market segment - Pharma other")
Future (predicted) profit of the market as a whole
PainReform develops long-acting, non-opioid pain medications. Demand for such products is driven by medical necessity. However, overall economic conditions, reflected in this graph, can influence the speed of commercialization. During periods of growth, hospitals and insurance systems are more willing to implement new, albeit more expensive, but effective technologies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772564115778 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - PainReform Ltd.
PainReform Ltd. is a clinical-stage pharmaceutical company specializing in the development of long-acting, non-opioid pain relievers. This metric, which compares its market capitalization with virtually zero revenue, reflects its potential. It demonstrates investors' belief that its product will become a sought-after alternative in the post-surgical pain market.
P/S market segment - Pharma other
PainReform Ltd. is a pharmaceutical company developing a long-acting, non-opioid pain reliever for post-operative use. The company's goal is to offer a safer alternative to opioids. This chart shows investor estimates of pharmaceutical revenue, reflecting expectations for the commercial potential of PainReform's product.
P/S of the market as a whole
PainReform Ltd. is a clinical-stage pharmaceutical company developing a long-acting pain reliever for post-surgical pain management. This chart, showing the median revenue estimate, shows that investors value PainReform based on the potential commercial success of its single product candidate.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company PainReform Ltd.
PainReform Ltd. is a pharmaceutical company developing a non-opioid drug for post-surgical pain relief. This chart shows the market's estimate of its potential future revenue. It is based entirely on expectations of successful clinical trials and future demand for its product as an alternative to traditional painkillers.
%20P%2FS%20PainReform%20Ltd.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-PainReform-Ltd.&v=1772564115839 "The graph of the company's future (projected) P/S PainReform Ltd.")
Future (projected) P/S of the market segment - Pharma other
PainReform is an Israeli biopharmaceutical company developing a long-acting pain reliever for post-operative use. The chart shows the average estimated future revenue in the pharmaceutical sector. It helps understand how investors view the potential market for the company's product and its advantages over existing analgesics.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20other&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-other&v=1772564115854 "Future (projected) P/S market segment graph - Pharma other")
Future (projected) P/S of the market as a whole
PainReform (PRFX) is a pharmaceutical company developing long-acting pain medications for the post-operative period. Demand for effective pain relief is not dependent on economic cycles. This cycle is irrelevant to their business, which is driven by medical needs and surgeons' decisions.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772564115867 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales PainReform Ltd.
PainReform is a biotech company focused on developing non-opioid painkillers. While in clinical development, it has not yet generated revenue from sales of its product. Future revenue growth will depend on the successful completion of trials and commercialization of its post-operative pain management drug.
Sales of companies in the market segment - Pharma other
PainReform Ltd. is an Israeli pharmaceutical company developing a long-acting pain reliever for postoperative use. Currently in the clinical stage, it has no sales revenue yet. Its future revenue will depend on the successful commercialization of its lead product, PRF-110.
Overall market sales
PainReform Ltd. is developing long-acting non-opioid pain medications for the post-operative period. Demand for its products will be determined by the number of surgical procedures. This trend, reflecting the overall economic situation, influences the number of elective surgeries. During stable economic periods, people are more likely to undergo elective procedures, creating a market for PainReform.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company PainReform Ltd.
PainReform is a biopharmaceutical company developing a non-opioid drug for prolonged post-surgical pain relief. Future revenue depends on the success of clinical trials and the commercial launch of the product. This chart shows analysts' long-term expectations for the post-surgical pain relief market and the potential of their drug.
%20sales%20of%20the%20company%20PainReform%20Ltd.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-PainReform-Ltd.&v=1772564115966 "Schedule of future (projected) sales of the company PainReform Ltd.")
Future (projected) sales of companies in the market segment - Pharma other
PainReform Ltd. is a pharmaceutical company developing a long-acting pain reliever for postoperative use. This chart shows the forecast for the entire pharmaceutical sector. It reflects the overall need for new, more effective, and safer analgesics, which determines the market potential for PainReform's product.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-other&v=1772564115972 "Schedule of future (projected) sales of companies in the market segment - Pharma other")
Future (projected) sales of the market as a whole
Healthcare cost forecasts, which are part of the overall expectations in this chart, are important to PainReform. The pharmaceutical company develops post-operative pain relief medications. Demand for its products will depend on the number of surgeries performed and the willingness of clinics to implement new pain treatment methods.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772564116047 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality PainReform Ltd.
PainReform is a clinical-stage pharmaceutical company developing a long-acting, non-opioid pain reliever for post-operative use. This chart reflects its current status. Future profitability depends entirely on the success of clinical trials and the ability to offer the market an effective and safe alternative to opioids.
Market segment marginality - Pharma other
PainReform is a biopharmaceutical company specializing in the development of non-opioid, extended-release pain medications for the postoperative period. Profitability depends on the success of its products in clinical trials. This chart shows the average profitability in the pharmaceutical industry. It helps assess the relevance of PainReform's technology in the treatment of postoperative pain.
Market marginality as a whole
PainReform is a pharmaceutical company developing extended-release non-opioid pain medications. The product's commercial success will depend on its acceptance by the medical community and insurance companies. This schedule, reflecting the overall state of the economy, influences healthcare budgets and its willingness to implement new, more advanced medications.
Employees in the company, segment and market as a whole
Number of employees in the company PainReform Ltd.
PainReform Ltd. is a biopharmaceutical company developing long-acting non-opioid pain medications. This chart reflects a compact team focused on research and clinical trials. The small staff is typical for companies at this stage, where the primary value is generated through intellectual property rather than operations.
Share of the company's employees PainReform Ltd. within the market segment - Pharma other
PainReform develops medications for prolonged post-surgical pain relief, aiming to offer an alternative to opioids. This chart shows the company's share of the total number of specialists working in the field of pain management. This reflects its focus on solving an important medical problem and the potential of its technology to improve post-operative care.
Number of employees in the market segment - Pharma other
PainReform Ltd. is a pharmaceutical company developing extended-release pain medications based on existing anesthesia products. This chart, which reflects employment in the pharmaceutical industry, illustrates the overall trend. The growing number of specialists working on new drug delivery systems demonstrates the demand for improved and more convenient therapeutic solutions for patients.
Number of employees in the market as a whole
PainReform develops medications for long-term post-surgical pain relief. Their market is the healthcare system. This employment rate chart reflects the number of people with access to quality healthcare through insurance. A stable labor market provides funding for hospitals seeking to improve treatment outcomes and shorten patient stays using new medications.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company PainReform Ltd. (PRFX)
PainReform is an Israeli pharmaceutical company developing new formulas for post-operative pain relief. This chart shows the valuation of their R&D. The company's value is derived from its patent for the drug reformulation, not its manufacturing capacity. A small team of scientists and managers manages intellectual property that the market values with high potential.
%20of%20the%20company%20PainReform%20Ltd.%20(PRFX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-PainReform-Ltd.-PRFX&v=1772564116196 "Chart of market capitalization per employee (in thousands of dollars) of the company PainReform Ltd. (PRFX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma other
PainReform is a pharmaceutical company focused on developing new forms of pain relief medications. During clinical trials, its primary assets are patents and scientific data, not manufacturing capacity. This chart shows how the market values the intellectual capital generated by a small team of specialists compared to other players in the pharmaceutical industry.
%20by%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-other&v=1772564116259 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma other")
Market capitalization per employee (in thousands of dollars) for the overall market
PainReform develops extended-release pain medications for post-operative use. It is a focused pharmaceutical company. This chart illustrates how market value in this industry depends on the success of clinical trials for a single key product, developed by a small, highly specialized team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772564116284 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company PainReform Ltd. (PRFX)
PainReform is an Israeli biotech company developing a formula for prolonged post-surgical pain relief. Their goal is to reduce the need for opioids. This chart reflects their status: they are an R&D company that spends (negative return) capital per employee to conduct clinical trials and obtain regulatory approval.
%20Chart%20PainReform%20Ltd.%20(PRFX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-PainReform-Ltd.-PRFX&v=1772564116327 "Company Profit Per Employee (in thousands of dollars) Chart PainReform Ltd. (PRFX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma other
PainReform develops drugs for post-operative pain relief. For a pharmaceutical company in the development stage, this chart reflects not so much current profitability as resource management efficiency. Negative values are normal, but investors monitor the dynamics in the context of clinical trial news, which determines future profitability.
%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-other&v=1772564116334 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma other")
Profit per employee (in thousands of dollars) for the market as a whole
PainReform (PRFX) is an Israeli biopharmaceutical company developing extended-release pain medications (based on ropivacaine) for postoperative care. It is a clinical-stage R&D company with no profit. This negative metric reflects the investment in research and development personnel dedicated to the development and clinical trials of the new product.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772564116339 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee PainReform Ltd. (PRFX)
PainReform Ltd. is developing a new formulation for post-operative pain relief. There is no revenue at the clinical trial stage. This graph is important for investors as a measure of future potential: a successful product can generate significant revenue with the help of a small team.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-PainReform-Ltd.-PRFX&v=1772564116367 "Sales chart per company employee PainReform Ltd. (PRFX)")
Sales per employee in the market segment - Pharma other
PainReform is an Israeli clinical-stage biotech company specializing in post-surgical pain treatments. They have no commercial revenue. This chart clearly illustrates their R&D model. The productivity of their small team of doctors and scientists is measured not by revenue, but solely by success in clinical trials.
Sales per employee for the market as a whole
Global Industrial (GIC) distributes a wide range of industrial and office equipment (MRO) through catalogs and e-commerce. Their business is at the intersection of logistics and digital commerce. This chart demonstrates the effectiveness of their distribution model. Success depends on warehouse automation and the efficiency of their online platform, which enable them to process thousands of orders with minimal staff involvement.
Short shares by company, segment and market as a whole
Shares shorted by company PainReform Ltd. (PRFX)
PainReform (PRFX) is an Israeli company developing a new painkiller formula for post-operative use. This chart tracks bearish bets. Shorts may reflect doubts that the company's drug will be significantly better than existing, cheaper generic versions, or that it will fail clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-PainReform-Ltd.-PRFX&v=1772564116476 "Short Shares Chart for the Company PainReform Ltd. (PRFX)")
Shares shorted by market segment - Pharma other
PainReform (PRFX) is developing a new formula for long-term post-surgical pain relief, aiming to reduce opioid dependence. The chart below shows the overall short position on the biotech sector, demonstrating the level of investor confidence in the ability of small companies to bring new solutions to market in this complex field.
Shares shorted by the overall market
PainReform is an Israeli biotech company developing formulas for long-term pain relief after surgery. This chart measures overall fear. When investors are afraid, they avoid stocks with dual risks: scientific (trial failure) and geopolitical (Israel). PRFX falls victim to risk aversion when panic mounts in the market due to general macroeconomic threats.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator PainReform Ltd. (PRFX)
This chart for PainReform is a barometer of pain management bets. The company is developing an extended-release formulation (PRF-110) for post-surgical pain. "Overbought" (above 70) occurs in anticipation of Phase 3 trial data. Failure to meet endpoints or FDA delays immediately sends the stock into "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-PainReform-Ltd.-PRFX&v=1772564116525 "RSI 14 indicator chart for the company's stock PainReform Ltd. (PRFX)")
RSI 14 Market Segment - Pharma other
PainReform is an Israeli biopharmaceutical company specializing in the treatment of post-surgical pain. Their key product, PRF-110, is a long-acting pain-relieving gel. This chart reflects the overall sentiment in the biotech sector, helping to assess the overall market sentiment toward this speculative industry.
RSI 14 for the overall market
PainReform (PRFX) is a pharmaceutical company developing new formulas for post-surgical pain relief. Its success depends on regulatory approval and R&D funding. This market "temperature" chart shows overall risk appetite. When the market is "overheated" (euphoria), investors are eager to fund biotech. During periods of panic (oversold), the shares of companies without revenue, like PRFX, come under intense pressure.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PRFX (PainReform Ltd.)
PainReform is an Israeli biotech company developing a drug (PRF-110) for long-term (non-opioid) pain relief after surgery. This chart shows the speculative average 12-month price target from analysts, which is based almost entirely on their assessment of clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PRFX-PainReform-Ltd.&v=1772564116557 "A chart showing analyst consensus forecasts for the expected stock price. PRFX (PainReform Ltd.)")
The difference between the consensus estimate and the actual stock price PRFX (PainReform Ltd.)
PainReform is an Israeli biotech company developing a drug (PRF-110)—a long-acting pain-relieving gel for post-operative care. This chart shows the difference between the market valuation and the consensus forecast. It reveals whether experts believe in their R&D program and their ability to compete in the anesthetic market.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PRFX-PainReform-Ltd.&v=1772564116562 "A chart showing the difference between the consensus forecast and the actual stock price. PRFX (PainReform Ltd.)")
Analyst consensus forecast for stock prices by market segment - Pharma other
PainReform is an Israeli R&D biotech company developing a non-opioid patch (PRF-110) for post-surgical pain relief. This chart reflects analysts' overall expectations for the pharmaceutical sector. It shows whether experts believe the market for "safe" painkillers is growing or whether they consider it overheated.
Analysts' consensus forecast for the overall market share price
PainReform is a biotech company developing a non-opioid drug (PRX-100) for long-term relief of post-surgical pain. This chart shows the overall market "risk appetite." For PRFX, a clinical-stage company, overall market optimism (as shown by the rising chart) is critical for attracting capital for R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index PainReform Ltd.
PainReform is a non-opioid biotech. Their signature product is PRF-110, a long-acting (72 hours) anesthetic gel (based on ropivacaine), which (they claim) will replace opioids for post-surgical pain. This graph is a pure indicator of their R&D. Its dynamics are all or nothing, depending entirely on their (very risky) clinical trial data.
AKIMA Market Segment Index - Pharma other
PainReform is an Israeli pharmaceutical company solving a pressing problem. They are developing a non-opioid, but rather a long-acting pain reliever for post-surgical use. This is a direct response to the opioid crisis. This chart compares their composite index to the sector, showing how their pain relief alternative stacks up against the competition.
The AKIM Index for the overall market
PainReform is an Israeli pharmaceutical company that reformulates well-known painkillers to prolong their effectiveness (for post-operative pain). This chart, reflecting the market average, provides a macro backdrop. It helps assess how PRFX, which improves treatment standards, compares to overall economic trends.
